摘要
目的系统评价恩度联合化疗治疗晚期结直肠癌的有效性和安全性。方法计算机检索Cochrane图书馆、PubMed、Embase、CNKI、CBM、VIP,中华医学会数字化期刊。检索年限均为建库至2013年1月。按Cochrane系统评价员手册对纳入文献的方法学质量进行评价后,提取数据,采用RevMan 5.2统计软件行Meta分析。结果共纳入5个随机对照试验,包括220例病例。Meta分析结果显示恩度联合化疗较单纯化疗而言,其疾病的恩度联合化疗组的CR(10.91%vs 2.73%,RR=4.08,95%CI:1.19-13.95,P=0.02)、PR(48.18%vs 30.91%,RR=2.18,95%CI:1.23-3.87,P=0.007)、PD(15.45%vs 41.82%,RR=0.25,95%CI:0.13-0.47,P<0.0001)、RR(60.00%vs 33.64%,RR=3.23,95%CI:1.79-5.81,P<0.0001)、CBR(82.73%vs 55.45%,RR=4.30,95%CI:1.19-13.95,P<0.0001)方面均显示出优势。恩度的主要不良反应包括恶心、呕吐、便秘、心慌、心电图改变等。结论恩度联合化疗对于晚期结直肠癌疗效较好,恩度联合化疗药物可作为治疗晚期结直肠癌的常规药物。
Objective To evaluate the safety and efficacy of Endostar combined with chemotherapy in the treatment of end-stage colorectal cancer. Methods The relevant randomized controlled trials were retrieved from the electronic databases of Cochrane library, PubMed, EMbase, CNKI, CBM, VIP and Chinese Medical Association. The retrieval time limit was from the database construction to January 2013. The data were extracted from eligible studies assessed for methodological quality according to Cochrane handbook for systematic reviews and analyzed using RevMan 5.2 software. Results Five randomized controlled trials involving 220 cases were included for meta-analysis. The results showed that Endostar combined with chemotherapy had an overall advantage over chemotherapy alone in terms of complete response rate （10.91%vs 2.73%RR=4.08, 95%CI：1.19-13.95, P=0.02）, partial response rate （48.18% vs 30.91% RR=2.18, 95% CI： 1.23-3.87, P=0.007）, progressive disease （15.45% vs 41.82% RR=0.25, 95% CI： 0.13-0.47, P＆lt;0.0001）, and the response rate （60.00% vs 33.64% RR=3.23, 95% CI： 1.79-5.81, P＆lt;0.0001）. Clinical benefit response（82.73%vs 55.45%RR=4.30,95%CI：1.19-13.95, P＆lt;0.0001）. The main adverse reactions included nausea, vomiting, constipation, palpitation, and electrocardiogram changes. Conclusion Endostar combined with chemotherapy is effective for advanced colorectal cancer and can be used as a routine treatment.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2014年第2期270-274,共5页
Journal of Southern Medical University
基金
暨南大学第一临床医学院科研培育基金(511005004)
关键词
恩度
晚期结直肠癌
META分析
随机对照实验
Endostar
advanced colorectal cancer
meta-analysis
randomized controlled trials
